Cosmos Health Accelerates U.S. Expansion: Liv18 Phase 1 Execution Complete; Production and Sales Commencing April 2026; Expected to Generate $5M+ in Annual Revenue at ~75% Gross Margins; Early U.S. Commercial Traction Observed Across Product Portfolio
Health Care
Free account required
Sign up free to keep reading
Create a free Quantisnow account to read full insights, follow tickers, and get real-time alerts on filings, ratings, and regulatory news.